The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 2735-2740

  Ishida, Ryoji ^a   Iwai, Miwako ^a,b   Hara, Akira ^b   Andoh, Toshiwo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Colony formation; Combination chemotherapy; ICRF 193; Topoisomerase II inhibitor; VP 16

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN KB; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; ENZYME DEGRADATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ETOPOSIDE; HUMANS; PIPERAZINES; TUMOR CELLS, CULTURED;

EID: 0029909081     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Wang JC: DNA topoisomerases. Annu Rev Biochem 54: 665-697, 1985.
2. Gellert M: DNA topoisomerases. Annu Rev Biochem 50: 879-910, 1981.
3. Watt PM and Hickson ID: Structure and function of type II DNA topoisomerases. Biochem J 303: 681-695, 1944.
4. Chung TDY, Drake FH, Tan KB, Per SR, Crook ST and Mirahelli CK: Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 86: 9431-9435, 1989.
5. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
6. Drlica K and Franco RJ: Inhibitors of DNA topoisomerases. Biochemistry 27: 2253-2259, 1988.
7. Tanahe K, Ikegami Y, Ishida, R and Andoh, T: Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51: 4903-4908, 1991.
8. Ishida R, Miki, T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K and Andoh T: Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51: 4909-4916, 1991.
9. Ishida R, Tanabe K, Narita T Sato M, Yui R, Utsumi KR and Andoh T: Mechanism of action of noncleavable complex-forming type of topoisomerase II inhibitors, bis(2,6-dioxopiperazine) derivatives. In: T. Andoh, H. Ikeda and M. Oguro (eds.), Molecular Biology of DNA Topoisomerases and its Application to Chemotherapy, pp 207-214. Boca Raton, CRC Press, 1993.
10. Roca J, Ishida R, Berger JM, Andoh T and Wang JC: Antitumor bisdioxopiperazines inhibit yeast topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91: 1781-1785, 1994.
11. Creighton AM, Hellmann K and Whitecross S: Antitumor activity in a series of bisdiketopiperazines. Nature 222: 384-385, 1969.
12. Clarke DJ, Johnson RT and Downes CS: Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells independently of the generation of DNA strand breaks. J Cell Sci 105: 563-569, 1993.
13. Ishida R, Sato M, Narita T, Utsumi KR, Nishimoto T, Morita T, Nagata H and Andoh T: Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J Cell Biol 126: 1341-1351, 1994.
14. Hellmann K and Burrage K: Control of malignant metastases by ICRF-159. Nature (Lond.) 224: 273-275, 1969.
15. Herman EH, Witiak DT, Hellmann K, Waravdekar VS: Biological properties of 1CRF-159 and related his(dioxopiperazine) compounds. In: S. Garattini, A. Goldin, F. Hawking and I. J. Kopin (eds.), Advances in Pharmacology and Chemotherapy, pp. 249-291. New York, Academic Press. 1982.
16. Narita T, Yaguchi S, Komatsu T, Takase M, Hoshino A, Inaba M and Tsukagoshi S: Antitumor activity of MST-16. a novel derivative of bis(2,6-dioxopiperazine), in murine models. Cancer Chemother and Pharmacol 26: 193-197, 1990.
17. Narita T, Koide Y, Yaguchi S, Kimula S, Izumisawa Y, Takase M, Inuba M and Tsukagoshi S: Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine). Cancer Chemother and Pharmacol 28: 235-240, 1991.
18. Kano Y, Narila T, Suzuki K, Akutsu M, Suda K, Sakamoto S and Miura Y: The effect of ICRF-154 in combination with other anticancer agents in vitro. Br J Cancer 66: 281-286, 1992.
19. Bugg BY, Danks MK, Beck WJ and Suttle DP: Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci USA 88: 7654-7658, 1991.
20. Ishimi Y, Ishida R and Andoh T: Effect of ICRF-193, a novel DNA topoisomerase II inhibitor, on simian virus 40 DNA and chromosome replication in vitro. Mol Cell Biol 12: 4007-4014, 1992.
21. Ishimi Y, Ishida R and Andoh T: Synthesis of SV40 C-family catenated dimers in vivro in the presence of ICRF-193. J Mob Biol 247: 835-839, 1995.
22. Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC, and Andoh T: DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF193 in Saccharomyces cerevisiae. Cancer Res 55: 2299-2303, 1995.
23. Yang L, Wold MS, Li JJ, Kelly TJ and Liu LF: Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. Proc Natl Acad Sci USA 84: 950-954, 1987.
24. Drake FH, Hofmann GA, Mong SM, Bartus JOL, Hertzberg RP, Johnson RK, Mattern MR and Mirabelli CK: In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49: 2578-2583, 1989.
25. Jensen PB, Sorensen BS, Demant EJF, Sehested M, Jensen PS, Vindelov L and Hansen HH. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 50: 3311-3316, 1990.
26. Ohno R, Yamada K, Hirano M, Shirakawa S, Tanaka M, Oguri, T, Kodera Y, Mitomo Y, Ikeda Y, Yokomaku S, Kamiya O, Kobayashi M, Saito H and Kimura K: The Tokai Blood Cancer Study Group. Phase II study: Treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine). J Natl Cancer Inst 81: 1917-1921, 1989.
27. Ohnu R, Masaoka T, Shirakawa S, Sakamoto S, Hirano M, Hanada S, Yasunaga K, Yokomaku S, Mitomo Y, Nagai K, Yamada K and Furue, H for the MST-16 study group. Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative ot bis(2,6-dioxopiperazine). Cancer 71: 2217-2221, 1993.
28. Furue H, Niitani H, Nakao I, Hoshino A, Hasegawa K, Tsukagoshi S and Fujita H. Phase I study of MST-16. Jpn J Cancer Chemother 77: 1287-1294, 1990.